2',3' -dideoxyinosine (ddl) and 2' ,3' -dideoxythymidiene (d4T) have been reported to inhibit the multiplication of human immunodeficiency virus (HIV) in patients. ddl and d4T were administered subcutaneously to cynomolgus monkeys starting 8 h prior to inoculation with 10-50 infectious doses of simian immunodeficiency virus (SIV SM ) . ddl, at a daily dose of 3 x 3.6 mg kg-1 for 10 days significantly delayed the appearance of SIV SM p24/26 antigen. A significant delay in the appearance of SIV sM p24/26 antigen was also seen when using a daily dose of 3 x 1 mg kg-1 of d4T for 10 days. Neither ddl nor d4T prevented SIV SM infection despite administration prior to virus inoculation.
Introduction
An acute infection of cynomolgus monkeys (Macaca fascicularis) with simian immunodeficiency virus of sooty mangabey origin (SIV sM) (Fultz et al., 1986; McClure et aI., 1989) has recently been developed as a model for infections caused by the human immunodeficiency virus (HIV) in order to evaluate the in vivo effects of antiviral drugs (Putkonen et aI., 1989; Lundgren et sl., 1990 Lundgren et sl., , 1991 McClure et sl., 1990; B6ttiger et al., 1991; Ljungdahl-Stahle et et., 1991) . The effects of3'-azidothymidine (AZT) , foscarnet (PFA) and 2',3'-dideoxycytidine (ddC) in delaying SIV sM antigenaemia in monkeys correlated with the clinical effects on p24 antigenaemia in HIV-infected patients (Lundgren et al., 1990) . Furthermore 3' -tluorothymidine (FLT), which has a good effect against HIV and SIV in cell cultures, was shown to delay SIV sM antigenaemia better than AZT in this model (Lundgren et al., 1991) .
2' ,3' -Dideoxythymidiene (d4T) and 2',3' -dideoxyinosine (ddl) were chosen for evaluation in SIV-infected monkeys since these compounds have been evaluated in clinical trials in AIDS patients. The effect of ddl on p24 antigen in patients has been documented in several studies (Butler et aI., 1991; Cooley et aI., 1990a Cooley et aI., , 1990b Dolin et aI., 1990; Lambert et al., 1990; Rozencweig et al., 1990; Valentine et el., 1990; Yarchoan et al., 1990a Yarchoan et al., , 1990b . Less has been published about the clinical effects of d4T, but a reduction in p24 antigen level has been reported (M. Brown, personal communication; Squires et al., 1990, personal communication) . Furthermore it has been shown that SIV and HIV in cell culture assays have similar sensitivities to ddl and d4T (Tsai et al., 1990; R.F. Shinazi et al., personal communication; L. Vrang, Medivir, personal communication) .
To evaluate the in vivo effect of selected compounds and further validate the usefulness of the monkey model as a tool in selecting drugs and doses for clinical evaluation against HIV infections, we have tested the effects of d4T and ddl on SIV sM p24/26 antigenaemia in SIVsM-inoculated monkeys. Figure 1 shows the appearance of SIV sM p24/26 antigen in control animals and in monkeys treated with ddl. A significant delay (P < 0.05) in p24/26 antigen was observed for ddl-treated animals (n = 4) vs. control animals (n = 24). The time for antigen appearance in ddl-treated animals was 8.9d and in controls 6.6d. In monkeys treated with the high dose of d4T (3 x 1 mg kg-1 cr ', n = 4) the mean time for appearance of viral antigen (l.8d) was significantly delayed (P < 0.05) compared to the controls (6.6d), but the effect was less than for ddl ( Fig.  2a ). Treatment with a low dose of d4T (3 x 0.02 mg kg-1 o', n = 4), resulted in an appearance of viral antigen identical to that in control monkeys and no effect of this treatment was seen ( Fig. 2b) .
Results
No effect on the time of appearance of antibodies to SIV sM was seen in ddl-or d4T-treated animals when compared to controls (data not shown). All animals became infected with SIV sM, as determined by p24/26 antigen and seroconversion, despite treatment starting 8 h prior to virus inoculation. 0-0, Control monkeys (n = 24); __e, monkeys (n = 4) treated for 10d with 3 x 3.6mg kg-1 d-1 of ddl. 30 20 10
Discussion
The aim of this study was to further validate the acute SIV sM infection in cynomolgus monkeys as a model for preclinical evaluation of drugs against HIVIAIDS. Treatment with ddl and d4T, at clinically used doses, showed weak but significant effects on the SIV sM infection (Figs 1  and 2a ), confirming the relevance of this model in predicting clinical efficacy against HIV/AIDS. Treatment with d4T was less efficient than with ddl in delaying SIV sM antigen appearance (Figs 1 and 2a ). At the low dose of d4T (3 x 0.02 mg kg-1 d-1 ) the viral antigen appeared at the same time as in the controls (Fig. 2b) showing both the expected lack of effect and the reproducibility of the method. It seems at present unlikely that the dosing of ddl and d4T in the clinic could be much increased above that used in this study, because of toxicity (Rozencweig et al., 1990; Squires et al., 1990, personal communication) .
At the dose levels used in SIVsM-infected monkeys neither ddl nor d4T prevented infection despite dosing both 8 h prior to and 10 min prior to virus inoculation. This result is in accordance to observations that AZT, toscamet and ddC, using the same conditions, could not prevent infection with SIV SM in cynomolgus monkeys (Lundgren et sl., 1990 (Lundgren et sl., , 1991 . Treatment at a lower challenge dose of virus might have prevented infection, as has recently been found using FLT (B6ttiger et aI., personal communication) . A dose of virus which is to high could possibly explain the lack of prophylactic effect of 100mg kg-1 d-1 ofd4T given to SIV infected monkeys by McClure et al. (1990) .
HIV-1, HIV-2, and SIV seem to be quite similar in their sensitivity to d4T and also to ddl. d4T has in cell cultures been 10-20 times more active than ddl (Larder etal., 1990; Tsai et al., 1990; R.F. Shinazi et al., personal communication; L. Vrang, personal communication) . Despite this ddl showed a stronger effect than d4T against SIV sM infections in cynomolgus monkeys (Figs 1 and 2a ) at a dose level which was 3.6 times higher for ddl. The relative in vivo efficacy could be influenced by several factors among which are the in vivo half-lives of their triphosphates and relative rates of glucuronidation.
Both ddl and d4T are supposed to inhibit HIV and SIV after phosphorylation by cellular enzymes to triphosphates (in case of ddl to ddA triphosphate) which then inhibit the reverse transcriptases of HIV and SIV (Ho and Hitchcock, 1989; Mansuri et el., 1989; McGowan et al., 1990) . The phosphorylating enzymes in human and monkey cells are similar in their ability to phosphorylate nucleoside analogues (Habteyesus et el., 1991) . In these enzymatic steps ddl (ddA) and d4T have to compete with natural substrates and this means that differences could exist between cell culture effects and in vivo effects (Oberg, 1988) .
The plasma half-life of ddl in monkeys is 0.9-1.6 h (Qian et aI., 1991) and in humans is 0.6--1.3h (Hartman et al., 1990; Dolin et al., 1990) . d4T has a half-life in monkeys of 0.8-1.4 h (Schinazi et aI., 1990 ) and in man of over 5 h (AmFARTreatment Directory, vol 4, p 28, 1990) . However, the pharmacokinetics of the intracellularly active forms of ddl (ddATP) and of d4T (d4TIP) are not known in vivo, but (Ahluwalia et aI.,1988 ) and 3.3 h for d4TIP (Ho and Hitchcock, 1989) . A more quantitative determination of the similarity in effect of ddl and d4T against the acute SIVSM infection and HIV/AIDS requires both larger numbers of monkeys than were used here, and better quantitative data about effects on p24 in patients. However, the significant effects of ddl and d4T against the acute SIV SM infection in cynomolgus monkeys at dose levels active in patients adds two further drugs showing effect both in the human HIV infection and in the acute SIV SM monkey model.
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Materials and Experimental procedures
Methods
The methods used have been described earlier (Putkonen et el., 1989; Lundgren et el., 1990 Lundgren et el., , 1991 . Briefly, 4 cynomolgus monkeys in each treatment group were given one ml intravenously of SIV s M (McClure et al., 1989) containing a virus dose of 10-50 monkey infectious doses (MID so ). Values from the 4 control animals included in the experiment were pooled together with results from 20 control monkeys from previous experiments performed under the same conditions. The time for appearance of p24/26 in the 4 control animals and the 20 earlier control animals did not differ significantly. SIV s M had been grown in human peripheral blood lymphocytes (Lundgren et al., 1990 (Lundgren et al., , 1991 and the virus pool had been titrated in monkeys. A fresh tube of virus, stored at -70°C, was used at each infection and always had the same reverse transcriptase activity (not shown). At a dilution of 1/5000, 1 ml of the virus pool (II) corresponded to 10-50 MIDso• SIV s M was kindly provided by Drs P. Fultz and H. McClure (Yerkes Primate Research Center, Animal Resources Branch, NIH, .
Treatment
Treatment consisted of subcutaneous injections every 8 h for 10 days. The first and second treatments were given 8 h prior to and 10 min prior to virus inoculation, respectively. Serum samples from the monkeys were collected on days 0, 4, 6, 8, 10,14,17,22, and 30 . To be able to add the four control monkeys in this experiment to the group of previous controls, the average of p24/26 antigen values for days 17 and 22 was plotted as day 20. Monkeys given d4T (3 x 1mg kg-1 d") were bled on day 20 and not on days 17 and 22. The samples were kept frozen (-20°C) until screened for viral antigen and antibodies. The appearance of SIV s M p26 antigen in plasma was followed by a commercial ELISA-kit intended for HIV-1 p24 antigen (Abbott Laboratories, North Chicago). Antibodies to SIV s M were detected by a peptide ELISA method (Ljungdahl- Stahle et aI., 1991) .
Drugs and dose selection
d4T and ddl, obtained from Raylo Chemicals (Edmonton, Alberta, Canada), were dissolved in phosphate buffered saline and sterile filtered before use. The dose levels used were 3 x 3.6mg kg-1 d-1 of ddl, 3 x 0.02 mg kg-1 d-1 of d4T and 3 x 1.0 mg kg-1 d-1 of d4T. The dose level of ddl was selected on the basis of published clinical effects on HIV p24 antigen levels and maximal tolerated oral dose, estimated to be in an interval between 9.6-20.4mg kg-1 d-1 and an oral bioavailability of about 40% (Cooley et el., 1990a,b; Dolin et al., 1990; Lambert et al., 1990; Rozencweig et al., 1990; Valentine et al., 1990; Yarchoan et al., 1990a,b; Butler et al., 1991) . From a phase I study it has been reported that d4T reduced p24 antigenaemia at the lowest dose tested, 2mg kg-1 d-1 Squires et al., 1990, personal communication; M. Browne et al., personal communication) and an oral bioavailability of about 50% in monkeys has been found .
Statistics
A non-parametric method was used (Wilcoxons Rank Sum, one-tailed) for the comparison of differences in the time for viral antigen appearance as described by Lundgren et al. (1990) .
P-values < 0.05 were considered significant.
